Pyxis Oncology opened lower at $1.62, compared with its previous close of $1.64. In the last trading session, the stock traded between $1.52 and $1.63. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Pyxis Oncology is now worth
$ 12.75
Resulting in a loss of
$ 87.25 (87.25%)
Note: Past profits do not guarantee future returns.
Rating from 7 Analysts
Today's Change
$-0.07 (-3.96%)
Day High
$1.63
Day Low
$1.52
Day Open
$1.62
Prev Close
$1.64
Volume
9,25,782
1W Return
-4.89%
1M Return
-21.45%
3M Return
-44.05%
6M Return
-42.73%
1Y Return
-65.54%
Market Cap ($ Mn)
188
PE Ratio
-
PB Ratio
17.97
PEG Ratio
-
ROE
-91.80%
ROCE
-78.23%
EPS (TTM)
$-0.24
1 Week
-4.89%
1 Month
-21.45%
3 Months
-44.05%
6 Months
-42.73%
9 Months
16.67%
RBC Capital raises Pyxis Oncology price target to $7, maintains outperform
RBC Capital maintains an Outperform rating on Pyxis Oncology. Price target raised from $6 to $7 by analyst Leonid Timashev. Rating status remains unchanged despite the target increase.
6 days agoPyxis Oncology Q3FY26 Results: Net loss narrows to $20.0M, runway extends
Net loss narrowed to $20.0 million in Q3FY26 from $22.0 million in Q3FY25. Cash runway extended into first half of 2028 after $110 million public offering. Phase 3 trial initiation for MICVO planned for mid-2027 following FDA alignment. R&D expenses decreased to $16.6 million due to lower manufacturing costs.
7 days agoPyxis Oncology closes $110M offering; potential total hits $282.6M
Pyxis Oncology closed its registered public offering on October 1, 2026. Upfront gross proceeds totaled approximately $110.0 million before expenses. Common warrants allow for additional $172.6 million if fully exercised. Total potential gross proceeds from the transaction reach $282.6 million. Proceeds will fund MICVO clinical trials including the Headliner Phase 3 study.
1mo agoPyxis Oncology terminates $150 million ATM offering without selling shares
Pyxis Oncology terminated its $150 million at-the-market offering. Zero shares were sold under the agreement with Leerink Partners. The Sales Agreement remains active but requires new filings for future sales. Termination frees up capacity under Form S-3 registration statement.
1mo agoPyxis Oncology to present updated Phase 1 data for micvotabart pelidotin
Pyxis Oncology to present Phase 1 monotherapy data for micvotabart pelidotin on September 9, 2026. Analysis focuses on patients treated at 5.4 mg/kg dose cap in recurrent/metastatic HNSCC. MICVO retains FDA Fast Track Designation for second-line and beyond treatment settings. Event features clinical expert Alan L. Ho from Memorial Sloan Kettering Cancer Center.
2mo agoPyxis Oncology appoints Thomas Civik as CEO and Chairman
Thomas Civik appointed CEO and Chairman of Pyxis Oncology effective September 4, 2026. John Flavin transitions to Lead Independent Director, remaining on the board. Company expects fall 2026 data update for MICVO monotherapy in head and neck cancer. Fourth quarter 2026 update expected for MICVO combination study with pembrolizumab.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Pyxis Oncology is now worth
$ 12.75
Resulting in a loss of
$ 87.25 (87.25%)
Note: Past profits do not guarantee future returns.
